Safety and Efficacy of Velcade in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function

Trial Profile

Safety and Efficacy of Velcade in Relapsed and/or Refractory Multiple Myeloma Patients With Impaired Renal Function

Discontinued
Phase of Trial: Phase II

Latest Information Update: 27 Aug 2013

At a glance

  • Drugs Bortezomib (Primary) ; Dexamethasone
  • Indications Multiple myeloma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Janssen Inc
  • Most Recent Events

    • 03 Mar 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 11 Sep 2009 Planned end date changed from 1 May 2012 to 1 Dec 2010 as reported by ClinicalTrials.gov.
    • 30 Apr 2009 Investigational drug identified as 'Dexamethasone' as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top